Teva Pharma Industries Stock Investor Sentiment
TEVA Stock | USD 13.09 0.14 1.06% |
About 56% of Teva Pharma's investor base is looking to short. The analysis of overall sentiment of trading Teva Pharma Industries stock suggests that many investors are alarmed at this time. Teva Pharma's investor sentiment overview provides quick insight into current market opportunities from investing in Teva Pharma Industries. The current market sentiment, together with Teva Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Teva Pharma Industries stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Teva Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Teva Pharma Industries.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Teva Pharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Teva daily returns and investor perception about the current price of Teva Pharma Industries as well as its diversification or hedging effects on your existing portfolios.
Teva Historical Sentiment
Although Teva Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Teva, such as negative comments on social media and news outlets, may cause fear in the market and push Teva Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Teva.
Teva |
Teva Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Teva Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Teva Pharma Industries Historical Investor Sentiment
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Teva Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Teva Pharma.
Teva Pharma Maximum Pain Price across 2024-04-19 Option Contracts
Teva Pharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Teva Pharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Teva Pharma's options.
Far too much social signal, news, headlines, and media speculation about Teva Pharma that are available to investors today. That information is available publicly through Teva media outlets and privately through word of mouth or via Teva internal channels. However, regardless of the origin, that massive amount of Teva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Teva Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Teva Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Teva Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Teva Pharma alpha.
Teva Pharma Performance against NYSE Composite
Price Growth (%) |
Timeline |
1 | Biosimilars Market is growing at a CAGR of 23.5 percent from 2024 to 2030 by Exactitude Consultancy | 03/01/2024 |
2 | EVP, CFO Eliyahu Kalif Sells 77,550 Shares of Teva Pharmaceutical Industries Ltd | 03/08/2024 |
3 | GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US | 03/21/2024 |
4 | Disposition of 100000 shares by Mark Sabag of Teva Pharma at 13.5209 subject to Rule 16b-3 | 03/28/2024 |
5 | Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler Respiratory Program Teva an... | 04/01/2024 |
6 | Alvotech Hosts Audio Call for Investors at 815 am EDT on April 3, 2024 | 04/03/2024 |
7 | Teva, mAbxience partner on oncology biosimilar | 04/04/2024 |
8 | Disposition of 20599 shares by Richard Daniell of Teva Pharma subject to Rule 16b-3 | 04/08/2024 |
9 | Global Immunomodulator Market Valuation Set to Total a Staggering US 178 Billion by 2034, Spurred by Spike in Chronic Disease Prevalence | 04/10/2024 |
10 | Teva reports positive Phase 3 results for migraine drug AJOVY | 04/11/2024 |
11 | FDA approves Alvotech biosimilar of JJ top-selling drug Stelara | 04/16/2024 |
Check out Teva Pharma Hype Analysis, Teva Pharma Correlation and Teva Pharma Performance. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.